perylene has been researched along with Cutaneous T-Cell Lymphoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Akilov, O; Appel, J; Bhatia, N; Boh, E; Bohjanen, K; Carter, J; Dawes, K; DeSimone, JA; Donini, O; Duvic, M; Elston, D; Geskin, L; Girardi, M; Guitart, J; Haulenbeek, A; Huen, A; Kim, EJ; Kim, YH; Korman, NJ; Kuzel, TM; Lain, E; Lee, ST; Mangold, AR; Musiek, A; Nikbakht, N; Olsen, E; Pacheco, T; Pariser, D; Piette, W; Poligone, B; Pullion, C; Querfeld, C; Rook, AH; Rumage, A; Schaber, CJ; Seminario-Vidal, L; Shinohara, M; Straube, R; Wong, HK; Wood, GS; Zeitouni, N; Zwerner, JP | 1 |
| Cabana, B; Duvic, M; Rook, AH; Tobia, A; Vonderheid, EC; Wood, GS | 1 |
| Fox, FE; Niu, Z; Rook, AH; Tobia, A | 1 |
2 trial(s) available for perylene and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial.
Topics: Adult; Anthracenes; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Mycosis Fungoides; Ointments; Perylene; Photochemotherapy; Photosensitizing Agents; Skin Neoplasms; Treatment Outcome | 2022 |
A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anthracenes; Antineoplastic Agents; Female; Humans; Light; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Perylene; Photochemotherapy; Phototherapy; Placebos; Psoriasis; Skin Neoplasms; Treatment Outcome; Young Adult | 2010 |
1 other study(ies) available for perylene and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
Photoactivated hypericin is an anti-proliferative agent that induces a high rate of apoptotic death of normal, transformed, and malignant T lymphocytes: implications for the treatment of cutaneous lymphoproliferative and inflammatory disorders.
Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Cells, Cultured; Humans; Keratitis; Lymphocyte Activation; Lymphoma, T-Cell, Cutaneous; Methoxsalen; Perylene; Photochemotherapy; Skin Neoplasms; T-Lymphocytes; Ultraviolet Rays | 1998 |